Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737502 · ClinicalTrials.gov registry record · Phase 1
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01737502: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01737502 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737502, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
Interventions
- DRUG Sirolimus
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Auranofin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2023-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737502
The ClinicalTrials.gov registry entry for NCT01737502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT01737502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737502 about?
NCT01737502 is a clinical study titled "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer". This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period o...
What is the current status of trial NCT01737502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-05-14. Estimated completion is 2023-04-24.
What interventions are being tested in trial NCT01737502?
The interventions under investigation include: Sirolimus (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Auranofin (DRUG).
Who is sponsoring clinical trial NCT01737502?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.